Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL), Single-Dose Vial, ...

FDA Recall #D-0048-2024 — Class II — August 24, 2023

Recall #D-0048-2024 Date: August 24, 2023 Classification: Class II Status: Terminated

Product Description

Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL), Single-Dose Vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015. NDC 0338-0067-01

Reason for Recall

CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.

Recalling Firm

Baxter Healthcare Corporation — Deerfield, IL

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

472 vials

Distribution

Nationwide in the USA

Code Information

Lot# MKZSU02, Exp 6/30/2024

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated